- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00074321
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
A Phase I And Pharmacogenetic Study Of CPT-11, Oxaliplatin, And Capecitabine In Patients With Solid Tumors
Studieöversikt
Status
Detaljerad beskrivning
OBJECTIVES:
I. To define the maximally tolerated dose of the combination of CPT-11 (irinotecan hydrochloride), oxaliplatin, and capecitabine in three different populations, based on UDP glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) genotype (6/6, 6/7, and 7/7).
II. To identify any activity of this treatment combination in patients with metastatic cancer.
III. To examine the differences in the toxicity profile, especially pertaining to hematologic and gastrointestinal (GI), and the maximally tolerated dose of the combination of CPT-11, oxaliplatin and capecitabine with respect to the UGT1A1 haplotypes.
IV. Examine the effect of the UGT1A1 genotype on the pharmacokinetics of CPT-11 and its metabolites.
OUTLINE: This is a dose-escalation study. Patients are stratified according to UGT1A1 genotype (6/6 vs 6/7 [closed to accrual as of 8/24/06] vs 7/7).
Patients receive irinotecan hydrochloride intravenously (IV) over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine orally (PO) twice daily (QD) on days 2-15. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride, oxaliplatin, and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6-10 patients (for a total of 12 patients) receive treatment at that dose.
After completion of study treatment, patients are followed up at 3 months.
PROJECTED ACCRUAL: A total of 54-84 patients (12-22 for stratum I, 18-28 for stratum II [closed to accrual as of 8/24/06], and 24-34 for stratum III) will be accrued for this study within approximately 4.4 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Histologically confirmed solid tumor for which there is no known standard therapy that is potentially curative or capable of extending life expectancy
- Unresectable disease
- Willing to provide biologic specimens to determine UGT1A1 genotype
No CNS metastases
- Prior CNS metastases allowed provided patient was treated with surgery and/or radiotherapy and is stable for more than 8 weeks
- Performance status - ECOG 0-2
- At least 12 weeks
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9.0 g/dL
- Bilirubin no greater than upper limit of normal (ULN) for patients with 6/6 UGT1A1 genotype (1.5 times ULN for patients with 6/7 [closed to accrual as of 8/24/06] or 7/7 UGT1A1 genotype)
- AST no greater than 3 times ULN (5 times ULN if there is liver involvement)
- Creatinine no greater than 1.5 times ULN
- No New York Heart Association class III or IV heart disease
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior allergy to platinum compounds, irinotecan, or to antiemetics or antidiarrheals appropriate for administration with study therapy
- No uncontrolled infection
- No seizure disorder
- No peripheral neuropathy grade 2 or greater
- More than 4 weeks since prior biologic therapy
- More than 4 weeks since prior immunotherapy
- No concurrent immunotherapy
- No concurrent prophylactic colony-stimulating factor therapy
- More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered
- No other concurrent chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior radiotherapy
- No prior radiotherapy to more than 25% of the bone marrow
- No concurrent radiotherapy
- See Disease Characteristics
- No other concurrent investigational therapy
- No concurrent sorivudine, brivudine, lamivudine, or stavudine
- No concurrent enrollment in any other study involving a pharmacologic agent for symptom control or therapeutic intent
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Arm I
Patients receive irinotecan hydrochloride IV over 90 minutes and oxaliplatin IV over 2 hours on day 1 and capecitabine PO QD on days 2-15.
Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
|
Korrelativa studier
Givet IV
Andra namn:
Korrelativa studier
Andra namn:
Givet PO
Andra namn:
Givet IV
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
MTD defined as one dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) assessed using NCI CTCAE v3.0
Tidsram: 3 weeks
|
3 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Tid till eventuell behandlingsrelaterad toxicitet
Tidsram: Upp till 3 månader
|
Kommer att sammanfattas beskrivande.
|
Upp till 3 månader
|
Tid till behandlingsrelaterad grad 3+ toxicitet
Tidsram: Upp till 3 månader
|
Kommer att sammanfattas beskrivande.
|
Upp till 3 månader
|
Dags för progression
Tidsram: Upp till 3 månader
|
Kommer att sammanfattas beskrivande.
|
Upp till 3 månader
|
Dags till behandlingsmisslyckande
Tidsram: Från registrering till dokumentation av progression, oacceptabel toxicitet eller vägran att fortsätta delta av patienten, bedömd upp till 3 månader
|
Kommer att sammanfattas beskrivande.
|
Från registrering till dokumentation av progression, oacceptabel toxicitet eller vägran att fortsätta delta av patienten, bedömd upp till 3 månader
|
Incidence of UTG1A1*28 polymorphism
Tidsram: Up to 3 months
|
The overall incidence of UTG1A1*28 polymorphism will be estimated and summarized in this patient population.
In addition, the incidence of this polymorphism will be explored in relation to tumor type.
|
Up to 3 months
|
Adverse events profile assessed using NCI CTCAE v3.0
Tidsram: Up to 3 months
|
The number and severity of all adverse events (overall, by dose level, and by tumor group) will be tabulated and summarized for the three patient groups.
The grade 3+ adverse events will also be described and summarized in a similar fashion.
|
Up to 3 months
|
Toxicity profile assessed using NCI CTCAE v3.0
Tidsram: Up to 3 months
|
Overall toxicity incidence as well as toxicity profiles by dose level, patient and tumor site will be explored and summarized in each of the two groups.
Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.
|
Up to 3 months
|
Response profile using RECIST criteria
Tidsram: Up to 3 months
|
Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as table and progressive disease in the two patient populations (overall and by tumor group).
|
Up to 3 months
|
Time until hematologic nadirs (WBC, ANC, platelets)
Tidsram: Up to 3 months
|
Will be summarized descriptively.
|
Up to 3 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NCI-2012-01444
- MC0311
- NCI-6240
- CDR0000344367
- MAYO-MC0311
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på laboratoriebiomarköranalys
-
Recep Tayyip Erdogan University Training and Research...Hacettepe UniversityAvslutadAmputation | Diabetisk polyneuropatiKalkon
-
Liao Jian AnRekryteringHuvud- och halscancerTaiwan
-
Oregon Health and Science University4DMedicalAnmälan via inbjudanLungsjukdomar | KOL | Luftvägssjukdom | DyspnéFörenta staterna
-
Progenity, Inc.AvslutadDowns syndrom | Aneuploidi | DiGeorges syndrom | Turnersyndrom | Klinefelters syndrom | Kromosomradering | Edwards syndrom | Pataus syndromFörenta staterna
-
University of California, San FranciscoRekryteringFriska | Fertilitetsstörningar | Manlig infertilitet | Infertilitet, manligFörenta staterna
-
Modarres HospitalAvslutadKomplikationer | Bildvägledd biopsi | Njure GlomerulusIran, Islamiska republiken
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadOkändYrkesmässig exponering | Muskuloskeletala sjukdomarChile
-
Healthy.io Ltd.Avslutad
-
Duke UniversityIndragenAntikoagulations- och trombostest (AT-POCT)Förenta staterna
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteAvslutadSpädbarnsdödlighet | BCGGuinea-Bissau